Status:
COMPLETED
Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network
Lead Sponsor:
National Institute of Mental Health (NIMH)
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
This study will test whether a cognitive remediation program to treat people with schizophrenia can be successfully implemented in a network of research clinics.
Detailed Description
Neurocognitive impairments, or problems with thinking and brain function, are a core component of schizophrenia. Such impairments, which can range from moderate to severe, are strongly associated with...
Eligibility Criteria
Inclusion
- Demonstrates adequate decisional capacity to make a choice about participating in the research study
- Diagnosis of schizophrenia or schizoaffective disorder, as defined by DSM-IV-TR criteria and confirmed by the Structured Clinical Interview for DSM-IV (SCID)
- Positive and Negative Syndrome Scale (PANSS) hallucinatory behavior, unusual thought content, and conceptual disorganization ratings of no greater than moderately severe (i.e., item scores must be less than or equal to 5)
- Meets all of the following cognitive performance and English language criteria:
- Learned English before age 12
- Able to complete the baseline Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) validly, based on the judgment of the investigator
- Raw score of 37 or greater on the Wide Range Achievement Test, reading subtest, 3rd edition (WRAT-3), used to establish minimum sixth grade reading level and estimated premorbid IQ
- Able to state specific goals relevant to the intervention that participant would like to achieve
- Able to participate in the computerized intervention, based on the judgment of the investigator
Exclusion
- Psychiatric hospitalization within 8 weeks of random assignment
- Adjustment to antipsychotic treatment within 4 weeks of random assignment
- Currently taking an anticholinergic medication
- DSM-IV diagnosis of alcohol or substance abuse (other than nicotine) within the last month or a DSM-IV diagnosis of alcohol or substance dependence (other than nicotine) within the last 6 months
- History of mental retardation, pervasive developmental disorder, or other neurological disorder (such as a traumatic brain injury, epilepsy, or Parkinson 's disease)
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00930150
Start Date
July 1 2009
End Date
February 1 2010
Last Update
April 19 2011
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University/Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519
2
Emory University
Atlanta, Georgia, United States, 30329
3
Medical College of Georgia
Augusta, Georgia, United States, 30912
4
University of Iowa Hospital
Iowa City, Iowa, United States, 52242